Intrexon (NASDAQ:XON) Trading 5.6% Higher

Intrexon Corp (NASDAQ:XON)’s stock price traded up 5.6% on Friday . The company traded as high as $7.14 and last traded at $7.01, 1,176,267 shares changed hands during trading. A decline of 45% from the average session volume of 2,155,860 shares. The stock had previously closed at $6.64.

A number of analysts have weighed in on the stock. BidaskClub downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. ValuEngine raised shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Northland Securities reaffirmed a “hold” rating and set a $10.00 price objective on shares of Intrexon in a research report on Monday. Finally, Bank of America reduced their price objective on shares of Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $17.00.

The company has a market capitalization of $1.09 billion, a P/E ratio of -5.12 and a beta of 2.22. The company has a current ratio of 3.55, a quick ratio of 3.57 and a debt-to-equity ratio of 0.90. The firm has a 50-day moving average of $7.49.

Intrexon (NASDAQ:XON) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05. The company had revenue of $35.99 million during the quarter, compared to the consensus estimate of $29.62 million. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. The company’s quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.51) EPS. Sell-side analysts predict that Intrexon Corp will post -1 earnings per share for the current year.

In other Intrexon news, CEO Randal J. Kirk purchased 301,670 shares of Intrexon stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average price of $4.63 per share, with a total value of $1,396,732.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Thomas Bostick sold 4,359 shares of Intrexon stock in a transaction on Monday, July 1st. The shares were sold at an average price of $7.76, for a total transaction of $33,825.84. Following the completion of the sale, the chief operating officer now directly owns 40,236 shares of the company’s stock, valued at approximately $312,231.36. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 1,706,993 shares of company stock valued at $8,319,188 and have sold 22,672 shares valued at $173,474. Company insiders own 44.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC bought a new position in Intrexon during the 2nd quarter valued at $58,000. B. Riley Wealth Management Inc. bought a new stake in shares of Intrexon during the 1st quarter worth $78,000. PFG Advisors raised its stake in shares of Intrexon by 21.7% during the 2nd quarter. PFG Advisors now owns 12,350 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,200 shares during the period. Aperio Group LLC bought a new stake in shares of Intrexon during the 2nd quarter worth $94,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Intrexon during the 2nd quarter worth $115,000. 70.83% of the stock is owned by institutional investors and hedge funds.

About Intrexon (NASDAQ:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.